SECsense Logo

XOMA Royalty Corporation's Key Acquisition Report: Pulmokine, Inc.

$XOMA
Form 8-K/A
Filed on: 2025-02-11
Source
XOMA Royalty Corporation's Key Acquisition Report: Pulmokine, Inc.

Here are the key insights and important information extracted from the provided financial report section:

  1. Entity Information:
  • Company Name: XOMA Royalty Corporation
  • CIK Number: 0000791908
  • Location: 2200 Powell Street Suite 310, Emeryville, CA 94608
  • Contact Number: (510) 204-7200
  • Stock Listings:
    • Common Stock: $0.0075 par value
    • Series A Cumulative Perpetual Preferred Stock: 8.625% with a par value of $0.05 per share (Ticker: XOMAP)
    • Series B Cumulative Perpetual Preferred Stock: 8.375% represented by Depositary Shares (each representing 1/1000th interest in a share; Ticker: XOMAO)
  1. Financial Event:
  • Acquisition: XOMA completed the acquisition of Pulmokine, Inc. on December 2, 2024.
  • Transaction Details: The acquisition was executed under an Agreement and Plan of Merger dated November 26, 2024, for a cash payment of $20 million at closing.
  1. Filing Information:
  • Filing Type: Amendment to Form 8-K (Original Form 8-K filed on December 2, 2024)
  • Purpose of Amendment: To include historical financial statements and pro forma financial information for Pulmokine, which were required under Items 9.01(a) and 9.01(b) of Form 8-K.
  1. Regulatory Compliance:
  • The amendment serves to supplement the information initially reported without altering other content from the Original Form 8-K.
  1. Important Dates:
  • Original Filing Date: December 2, 2024
  • Merger Agreement Date: November 26, 2024

This information highlights XOMA's business activities, specifically a significant acquisition, and ensures compliance with SEC regulations by providing additional required financial disclosures.